Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence

被引：119
作者：
Wang, XB
Kakoulidou, M
Giscombe, R
Qiu, QH
Huang, DR
Pirskanen, R
Lefvert, AK
机构：
[1] Karolinska Hosp, Karolinska Inst, Res Immunol Unit, Dept Med,Ctr Mol Med, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden
[3] Karolinska Inst, Dept Neurol, Stockholm, Sweden
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2002年 / 130卷 / 1-2期
关键词：
immune-associated antigen; myasthenia gravis; AT-rich sequence; gene expression; CTLA-4;
D O I：
10.1016/S0165-5728(02)00228-X
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cytolytic T lymphocyte-associated antigen-4 (CTLA-4) plays a critical role in the down-regulation of antigen-activated immune responses. The aberrant CTLA-4 expression is characterized by low surface and intracellular levels of CTLA-4 protein, impaired up-regulation of CTLA-4 in T cells in response to ConA stimulation and high levels of soluble CTLA-4 (sCTLA-4) in serum. The serum levels of sCTLA-4 are positively correlated with the serum concentration of antibodies against the acetylcholine receptor, The (AT), Polymorphism in the 3'-untranslated region contributes to decreased mRNA stability and, hence, to reduced expression of CTLA-4. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：224 / 232
页数：9
相关论文
共 47 条
[1]   CD28 function: A balance of costimulatory and regulatory signals [J].
Bour-Jordan, H ;
Bluestone, JA .
JOURNAL OF CLINICAL IMMUNOLOGY, 2002, 22 (01) :1-7
[2]   CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis [J].
Braun, J ;
Donner, H ;
Siegmund, T ;
Walfish, PG ;
Usadel, KH ;
Badenhoop, K .
TISSUE ANTIGENS, 1998, 51 (05) :563-566
[3]   CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression [J].
Carreno, BM ;
Bennett, F ;
Chau, TA ;
Ling, V ;
Luxenberg, D ;
Jussif, J ;
Baroja, ML ;
Madrenas, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1352-1356
[4]   AU-RICH ELEMENTS - CHARACTERIZATION AND IMPORTANCE IN MESSENGER-RNA DEGRADATION [J].
CHEN, CYA ;
SHYU, AB .
TRENDS IN BIOCHEMICAL SCIENCES, 1995, 20 (11) :465-470
[5]  
Chuang E, 1997, J IMMUNOL, V159, P144
[6]   CHANGES IN PERIPHERAL-BLOOD LYMPHOCYTE SUBSET FREQUENCIES IN MYASTHENIA-GRAVIS PATIENTS ARE RELATED TO IMMUNOSUPPRESSION [J].
CROSTI, F ;
ARMANINI, M ;
CONFALONIERI, P ;
ANTOZZI, C ;
MANTEGAZZA, R .
JOURNAL OF NEUROLOGY, 1994, 241 (04) :218-222
[7]   Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease [J].
Donner, H ;
Braun, J ;
Seidl, C ;
Rau, H ;
Finke, R ;
Ventz, M ;
Walfish, PG ;
Usadel, KH ;
Badenhoop, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (12) :4130-4132
[8]   B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28 [J].
Fallarino, F ;
Fields, PE ;
Gajewski, TF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (01) :205-210
[9]   Myasthenia gravis as a prototype autoimmune receptor disease [J].
Hoedemaekers, ACWE ;
Vriesman, PJCV ;
De Baets, MH .
IMMUNOLOGIC RESEARCH, 1997, 16 (04) :341-354
[10]   Genetic association of Ctla-4 to myasthenia gravis with thymoma [J].
Huang, D ;
Li, L ;
Norén, K ;
Xia, SQ ;
Trifunovic, J ;
Pirskanen, R ;
Lefvert, AK .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 88 (1-2) :192-198
12345